Health Trials

About this trial

To improve outcomes for childhood cancer patients through the implementation of precision medicine.

Eligibility criteria

Qualifiers

Age < 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate.

Life expectancy >6 weeks at time of enrolment

Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged <18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Whole Genome Sequencing
  • RNA seq
  • DNA Methylation
  • Targeted Panel Sequencing
  • High Throughput Sequencing (in vitro)
  • Patient Derived Xenograft (PDX)(in vivo)
  • Liquid Biopsy

Treatment groups

3,500 Participants
are divided into 13 treatment groups

13

Treatment groups

See each treatment group below.

Locations

11
Australia
Women's and Children's Hospital Adelaide Australia
Queensland Children's Hospital Brisbane Australia
Royal Hobart Hospital Hobart Australia
Monash Children's Hospital Melbourne Australia

Sponsors and collaborators

Australian & New Zealand Children's Haematology/Oncology Group

Lead sponsor

Children's Cancer Institute (CCI)

Collaborator

Minderoo Foundation

Collaborator

Medical Research Future Fund

Collaborator

Source ClinicalTrials.gov